NCT00260364View on ClinicalTrials.gov

Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle

DRUG

Capecitabine orally days 1 -21

DRUG

Erlotinib 100 mg orally days 1-28

DRUG

Bevacizumab 5 mg/kg intravenously every 2 weeks

Trial Locations (1)

SM2 5PT

The Royal Marsden Foundation Hospital NHS Trust, London and Surrey

All Listed Sponsors
collaborator

Professor Cunningham's Clinical Research Fund

UNKNOWN

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Royal Marsden NHS Foundation Trust

OTHER

NCT00260364 - Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter